Nationwide Survey of Telemedicinal Patient Education in IBD
Nationwide Survey of Telemedicinal Patient Education in IBD - Baseline Knowledge Gaps and a Randomized Comparison of Podcast Versus Written Format
The goal of this clinical trial is to learn if simple, easy-to-use educational materials can help people with inflammatory bowel disease (IBD) better understand their condition. The study will also look at how people feel about using these materials and if the education affects their daily life and well-being.
The main questions it aims to answer are:
- Does the education help people score higher on the IBD-KNOW questionnaire after three months
- How satisfied are people with the written or audio materials
- Does the education affect quality of life, mental health, or IBD disease activity
Researchers will compare written and audio education to see which format works better for learning and user experience.
Participants will:
- Fill out questionnaires at the start of the study and again after three months
- Receive written or audio educational materials if they are in one of the education groups
- Complete short surveys about quality of life, mental health, and IBD symptoms if they receive the educational materials
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Szeged, Ungheria, 6725
- University Of Szeged
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- IBD patients
- age ≥18 years
Exclusion Criteria:
- withdrawing consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Nessun intervento: CONT (Control)
The group not receiving any educational content.
|
|
|
Sperimentale: READ (Written PDF Document)
The group receiving the educational content in the form of a written PDF document.
|
A structured written PDF booklet covering key domains of inflammatory bowel disease, including anatomy, physiology, etiology, risk factors, pathology, diagnosis, treatments and targets, monitoring, surgeries, pregnancy, and vaccines.
The material is explicitly designed to address all questions related to the IBD-KNOW questionnaire, and was developed by expert gastroenterologists, ensuring comprehensive educational coverage.
|
|
Sperimentale: HEAR (Audio Podcast)
The group receiving the educational content in the form of an audio podcast.
|
A structured audio podcast covering key domains of inflammatory bowel disease, including anatomy, physiology, etiology, risk factors, pathology, diagnosis, treatments and targets, monitoring, surgeries, pregnancy, and vaccines.
The material is explicitly designed to address all questions related to the IBD-KNOW questionnaire, and was developed by expert gastroenterologists, ensuring comprehensive educational coverage.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Extended Inflammatory Bowel Disease Knowledge (IBD-KNOW) Questionnaire
Lasso di tempo: Three months after enrollment (CONT group) or receiving the educational material (READ and HEAR groups).
|
Change in the scores of the 35-item extended Inflammatory Bowel Disease Knowledge (IBD-KNOW) questionnaire to assess knowledge retention and evaluate user experience. The original IBD-KNOW questionnaire is a validated tool for measuring disease-related knowledge among patients with inflammatory bowel disease. It consists of 24 items covering anatomy and function, epidemiology, diet and lifestyle, general IBD knowledge, medications, complications, surgeries, pregnancy, and vaccinations. For this study, 11 additional items (items 25-35) were developed by IBD expert gastroenterologists to assess knowledge related to treatment, monitoring, and follow-up strategies. All items use simple True / False / Do not know response options. Total scores range from 0 to 35 points, with higher scores indicating better disease-related knowledge. |
Three months after enrollment (CONT group) or receiving the educational material (READ and HEAR groups).
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Likert Scale for Participant Satisfaction With Educational Content
Lasso di tempo: Three months after receiving the educational material (READ and HEAR groups).
|
Participant satisfaction with the educational material is measured using a 0-10 Likert scale to provide standardized, objective assessment of user experience. The scale ranges from 0 (not satisfied at all) to 10 (extremely satisfied), with higher scores indicating greater satisfaction with the educational content. |
Three months after receiving the educational material (READ and HEAR groups).
|
|
Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Follow-up
Lasso di tempo: Three months after receiving the educational material (READ and HEAR groups).
|
A follow-up questionnaire assessing patients' subjective experiences with telemedical education and its impact on quality of life using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ). The SIBDQ is a validated self-reported measure of health-related quality of life in IBD, consisting of 10 items, each rated on a 1-7 Likert scale. Total scores range from 10 to 70, with higher scores indicating better health-related quality of life. |
Three months after receiving the educational material (READ and HEAR groups).
|
|
Patient Health Questionnaire-9 (PHQ-9) Follow-up
Lasso di tempo: Three months after receiving the educational material (READ and HEAR groups).
|
A follow-up questionnaire assessing patients' subjective experiences with telemedical education and its impact on mental health using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a validated, self-administered 9-item depression severity scale, with each item scored from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms. An additional functional-impairment item asks how difficult the reported problems have made it for patients to work, manage household responsibilities, or interact with others. |
Three months after receiving the educational material (READ and HEAR groups).
|
|
Disease activity Follow-up
Lasso di tempo: Three months after receiving the educational material (READ and HEAR groups).
|
A follow-up questionnaire assessing patients' subjective experiences with telemedical education and its impact on disease activity. Participants rate agreement (Agree / Do not agree) with statements regarding lifestyle modification, disease management, frequency of flares and overall quality of life. |
Three months after receiving the educational material (READ and HEAR groups).
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- BM/21110-3/2023
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .